Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Achieve Life Sciences (QUIT) Stock Price & Analysis

1,808 Followers

QUIT Stock Chart & Stats

$6.45$0.05(0.78%)
At close: 4:00 PM EST
$7$8Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$6.29 - $6.56
52-Week Range
$2.62 - $8.64
Previous Close
$6.40
Volume
N/A
Average Volume (3M)
1.29M
Market Cap
$658.58M
Enterprise Value
$665.84M
Total Cash (Recent Filing)
$201.52M
Total Debt (Recent Filing)
$13.76M
Price to Earnings (P/E)
―
Beta
2.75
Next Earnings
Mar 11, 2027 (Est.)
EPS Estimate
-0.21
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Nicotine-Cessation Pipeline

A focused therapeutic strategy gives Achieve a clear development objective and aligns its resources around a substantial public-health need. If clinical and regulatory milestones are achieved, cytisinicline could support prescription sales, licensing, or commercialization partnerships.

Financial Leadership Continuity

The appointment adds an experienced finance leader during a period of significant capital needs and clinical execution. An orderly transition without reported financial-reporting disputes supports continuity in oversight as Achieve manages funding, development spending, and potential strategic opportunities.

Capital-Raising Flexibility

The ATM facility provides a flexible mechanism to fund important clinical and commercialization activities over the next several quarters. Access to capital can help maintain development momentum and extend operational capacity, although the eventual funding cost may include equity dilution.

Bears Say

No Commercial Revenue

Without an approved product-based revenue stream, Achieve cannot currently fund operations through customer sales. Its financial outlook therefore depends on successful clinical development and future commercialization, leaving revenue visibility and self-sustaining business economics highly uncertain.

Widening Losses And Cash Burn

Large and widening losses combined with persistent negative free cash flow indicate that the current operating model consumes substantial capital. Continued research and development spending will likely require external funding, increasing exposure to financing conditions and limiting financial resilience.

Negative Equity And Dilution Risk

Negative equity signals meaningful balance-sheet strain and reduces financial flexibility despite moderate absolute debt. Alongside ongoing cash burn, this condition raises reliance on new capital and increases the risk that future equity issuance could dilute existing shareholders.

Achieve Life Sciences News

QUIT FAQ

What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $2.62 and its highest was $8.64 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $658.58M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 119 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on Nov 10, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.09.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.21.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 102,902,490 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -5.605%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Hedge funds hold Achieve Life Sciences shares: the largest hedge-fund position in Achieve Life Sciences is 71,883,820 shares, and hedge funds increased their holdings by 4.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology